ORYZA PHARMACEUTICALS INC. Trademark

Trademark Overview


On Thursday, September 2, 2021, a trademark application was filed for ORYZA PHARMACEUTICALS INC. with the United States Patent and Trademark Office. The USPTO has given the ORYZA PHARMACEUTICALS INC. trademark a serial number of 97009108. The federal status of this trademark filing is EX PARTE APPEAL PENDING as of Tuesday, June 11, 2024. This trademark is owned by Oryza Pharmaceuticals, Inc.. The ORYZA PHARMACEUTICALS INC. trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

Pharmaceutical preparations for curing and alleviating various illnesses, namely, hypertension, angina pectoris, heart failure, various conditions accompanied by spasm of smooth muscle, namely, vascular spasm associated with acute myocardial infarction, angina pectoris, peripheral and pulmonary embolism, peripheral vascular disease with a vasospastic element and certain cerebral angiospastic states and visceral spasm, particularly ureteral, biliary or gastrointestinal, and attention deficit hyperactivity disorder; Nutraceuticals for use as a dietary supplement for the treatment of various dietary supplemental needs; Nutraceuticals for use as a dietary supplement

Pharmaceutical research and development; Development of pharmaceutical preparations and medicines
oryza pharmaceuticals inc.

General Information


Serial Number97009108
Word MarkORYZA PHARMACEUTICALS INC.
Filing DateThursday, September 2, 2021
Status760 - EX PARTE APPEAL PENDING
Status DateTuesday, June 11, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesPharmaceutical preparations for curing and alleviating various illnesses, namely, hypertension, angina pectoris, heart failure, various conditions accompanied by spasm of smooth muscle, namely, vascular spasm associated with acute myocardial infarction, angina pectoris, peripheral and pulmonary embolism, peripheral vascular disease with a vasospastic element and certain cerebral angiospastic states and visceral spasm, particularly ureteral, biliary or gastrointestinal, and attention deficit hyperactivity disorder; Nutraceuticals for use as a dietary supplement for the treatment of various dietary supplemental needs; Nutraceuticals for use as a dietary supplement
Goods and ServicesPharmaceutical research and development; Development of pharmaceutical preparations and medicines

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, October 15, 2021
Primary Code005
First Use Anywhere DateMonday, February 1, 2021
First Use In Commerce DateMonday, February 1, 2021

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, November 30, 2022
Primary Code042
First Use Anywhere DateTuesday, March 15, 2016
First Use In Commerce DateTuesday, March 15, 2016

Trademark Owner History


Party NameOryza Pharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCoral Springs, FL 33065

Trademark Events


Event DateEvent Description
Monday, September 6, 2021NEW APPLICATION ENTERED
Friday, October 15, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, May 31, 2022ASSIGNED TO EXAMINER
Friday, June 3, 2022NON-FINAL ACTION WRITTEN
Friday, June 3, 2022NON-FINAL ACTION E-MAILED
Friday, June 3, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, November 29, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, November 29, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, November 30, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Sunday, January 22, 2023NON-FINAL ACTION WRITTEN
Sunday, January 22, 2023NON-FINAL ACTION E-MAILED
Sunday, January 22, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, April 14, 2023APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Friday, April 14, 2023APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Thursday, July 20, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, July 20, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, July 21, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, August 10, 2023FINAL REFUSAL WRITTEN
Thursday, August 10, 2023FINAL REFUSAL E-MAILED
Thursday, August 10, 2023NOTIFICATION OF FINAL REFUSAL EMAILED
Thursday, November 9, 2023APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Thursday, November 9, 2023APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Thursday, February 8, 2024EXPARTE APPEAL RECEIVED AT TTAB
Thursday, February 8, 2024JURISDICTION RESTORED TO EXAMINING ATTORNEY
Thursday, February 8, 2024EX PARTE APPEAL-INSTITUTED
Tuesday, June 11, 2024ACTION CONTINUING FINAL - COMPLETED
Tuesday, June 11, 2024NOTIFICATION OF ACTION DENYING REQ FOR RECON E-MAILED
Tuesday, June 11, 2024ACTION DENYING REQ FOR RECON E-MAILED